Multiarmed Bandit Designs for Phase I Dose-Finding Clinical Trials With Multiple Toxicity Types

References

• Audibert, J.-Y., and Bubeck, S. (2010), “Best Arm Identification in Multi-Armed Bandits,” in COLT, Haifa, Israel, pp. 41–53.
   Google Scholar
• Auer, P., Cesa-Bianchi, N., and Fischer, P. (2002), “Finite-Time Analysis of the Multi-Armed Bandit Problem,” Machine Learning, 47, 235–256. DOI: 10.1023/A:1013689704352.
   Web of Science ®Google Scholar
• Aziz, M., Kaufmann, E., and Riviere, M.-K. (2021), “On Multi-Armed Bandit Designs for Phase I Clinical Trials,” Journal of Machine Learning Research, 22, 1–38.
   Web of Science ®Google Scholar
• Babb, J., Rogatko, A., and Zacks, S. (1998), “Cancer Phase I Clinical Trials: Efficient Dose Escalation With Overdose Control,” Statistics in Medicine, 17, 1103–1120. DOI: 10.1002/(SICI)1097-0258(19980530)17:10<1103::AID-SIM793>3.0.CO;2-9.
   PubMed Web of Science ®Google Scholar
• Bekele, B. N., and Thall, P. F. (2004), “Dose-Finding Based on Multiple Toxicities in a Soft Tissue Sarcoma Trial,” Journal of the American Statistical Association, 99, 26–35. DOI: 10.1198/016214504000000043.
   Web of Science ®Google Scholar
• Chen, Z., Tighiouart, M., and Kowalski, J. (2012), “Dose Escalation with Overdose Control Using a Quasi-Continuous Toxicity Score in Cancer Phase I Clinical Trials,” Contemporary Clinical Trials, 33, 949–958. DOI: 10.1016/j.cct.2012.04.007.
   PubMed Web of Science ®Google Scholar
• Chevret, S. (1993), “The Continual Reassessment Method in Cancer Phase I Clinical Trials: A Simulation Study,” Statistics in Medicine, 12, 1093–1108. DOI: 10.1002/sim.4780121201.
   PubMed Web of Science ®Google Scholar
• Ezzalfani, M., Zohar, S., Qin, R., Mandrekar, S. J., and Deley, M.-C. L. (2013), “Dose-Finding Designs Using a Novel Quasi-Continuous Endpoint for Multiple Toxicities,” Statistics in Medicine, 32, 2728–2746. DOI: 10.1002/sim.5737.
   PubMedGoogle Scholar
• Ivanova, A., and Kim, S. H. (2009), “Dose Finding for Continuous and Ordinal Outcomes with a Monotone Objective Function: A Unified Approach,” Biometrics, 65, 307–315. DOI: 10.1111/j.1541-0420.2008.01045.x.
   PubMed Web of Science ®Google Scholar
• Kalyanakrishnan, S., Tewari, A., Auer, P., and Stone, P. (2012), “PAC Subset Selection in Stochastic Multi-Armed Bandits,” in ICML (Vol. 12), pp. 655–662.
   Google Scholar
• Lee, S. M., Cheng, B., and Cheung, Y. K. (2011), “Continual Reassessment Method with Multiple Toxicity Constraints,” Biostatistics, 12, 386–398. DOI: 10.1093/biostatistics/kxq062.
   PubMed Web of Science ®Google Scholar
• Lee, S. M., and Cheung, Y. K. (2009), “Model Calibration in the Continual Reassessment Method,” Clinical Trials, 6, 227–238. DOI: 10.1177/1740774509105076.
   PubMed Web of Science ®Google Scholar
• Lin, R. (2018), “Bayesian Optimal Interval Design with Multiple Toxicity Constraints,” Biometrics, 74, 1320–1330. DOI: 10.1111/biom.12912.
   PubMed Web of Science ®Google Scholar
• Mu, R., Yuan, Y., Xu, J., Mandrekar, S. J., and Yin, J. (2019), “GBOIN: A Unified Model-Assisted Phase I Trial Design Accounting for Toxicity Grades, and Binary or Continuous End Points,” Journal of the Royal Statistical Society, Series C, 68, 289–308. DOI: 10.1111/rssc.12263.
   Web of Science ®Google Scholar
• O’Quigley, J. (2006), “Theoretical Study of the Continual Reassessment Method,” Journal of Statistical Planning and Inference, 136, 1765–1780. DOI: 10.1016/j.jspi.2005.08.003.
   Web of Science ®Google Scholar
• O’Quigley, J., Pepe, M., and Fisher, L. (1990), “Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer,” Biometrics, 33–48. DOI: 10.2307/2531628.
   PubMed Web of Science ®Google Scholar
• Villar, S. S., Bowden, J., and Wason, J. (2015), “Multi-Armed Bandit Models for the Optimal Design of Clinical Trials: Benefits and Challenges,” Statistical Science, 30, 199–215. DOI: 10.1214/14-STS504.
   PubMed Web of Science ®Google Scholar
• Wang, C., Chen, T. T., and Tyan, I. (2000), “Designs For Phase I Cancer Clinical Trials with Differentiation of Graded Toxicity,” Communications in Statistics – Theory Methods, 29, 975–987. DOI: 10.1080/03610920008832527.
   Web of Science ®Google Scholar
• Wheeler, G. M., Mander, A. P., Bedding, A., Brock, K., Cornelius, V., Grieve, A. P., Jaki, T., Love, S. B., Weir, C. J., Yap, C., Bond, S.J. (2019), “How To Design a Dose-Finding Study Using the Continual Reassessment Method,” BMC Medical Research Methodology, 19, 1–15. DOI: 10.1186/s12874-018-0638-z.
   PubMed Web of Science ®Google Scholar
• Yuan, Z., Chappell, R., and Bailey, H. (2007), “The Continual Reassessment Method for Multiple Toxicity Grades: A Bayesian Quasi-Likelihood Approach,” Biometrics, 63, 173–179. DOI: 10.1111/j.1541-0420.2006.00666.x.
   PubMed Web of Science ®Google Scholar